These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29138328)

  • 1. Reply to "Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?".
    Royer DJ; Carr DJJ
    J Virol; 2017 Dec; 91(23):. PubMed ID: 29138328
    [No Abstract]   [Full Text] [Related]  

  • 2. Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?
    Ghiasi H
    J Virol; 2017 Dec; 91(23):. PubMed ID: 29138327
    [No Abstract]   [Full Text] [Related]  

  • 3. Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling.
    Gottlieb SL; Giersing B; Boily MC; Chesson H; Looker KJ; Schiffer J; Spicknall I; Hutubessy R; Broutet N;
    Vaccine; 2019 Nov; 37(50):7336-7345. PubMed ID: 28647165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.
    Royer DJ; Gurung HR; Jinkins JK; Geltz JJ; Wu JL; Halford WP; Carr DJJ
    J Virol; 2016 Jun; 90(11):5514-5529. PubMed ID: 27030264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays.
    Blevins TP; Yu Y; Belshe RB; Bellamy AR; Morrison LA
    PLoS One; 2019; 14(4):e0214467. PubMed ID: 30946751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential prophylactic and therapeutic vaccines for HSV infections.
    Ramachandran S; Kinchington PR
    Curr Pharm Des; 2007; 13(19):1965-73. PubMed ID: 17627530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New concepts in herpes simplex virus vaccine development: notes from the battlefield.
    Dasgupta G; Chentoufi AA; Nesburn AB; Wechsler SL; BenMohamed L
    Expert Rev Vaccines; 2009 Aug; 8(8):1023-35. PubMed ID: 19627185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunobiology of herpes simplex virus (HSV) infections.
    Corey L
    Herpes; 2001 Mar; 8 Suppl 1():1A. PubMed ID: 11867026
    [No Abstract]   [Full Text] [Related]  

  • 9. T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?
    Posavad CM; Wald A; Hosken N; Huang ML; Koelle DM; Ashley RL; Corey L
    J Immunol; 2003 Apr; 170(8):4380-8. PubMed ID: 12682275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects and perspectives for development of a vaccine against herpes simplex virus infections.
    McAllister SC; Schleiss MR
    Expert Rev Vaccines; 2014 Nov; 13(11):1349-60. PubMed ID: 25077372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A protective role for herpes simplex virus type-1-specific humoral immunity in Alzheimer's Disease.
    Agostini S; Mancuso R; Baglio F; Clerici M
    Expert Rev Anti Infect Ther; 2017 Feb; 15(2):89-91. PubMed ID: 27882822
    [No Abstract]   [Full Text] [Related]  

  • 13. The potential of currently unavailable herpes virus vaccines.
    Rajčáni J; Bánáti F; Szenthe K; Szathmary S
    Expert Rev Vaccines; 2018 Mar; 17(3):239-248. PubMed ID: 29313728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines for herpes simplex virus infections.
    Koelle DM
    Curr Opin Investig Drugs; 2006 Feb; 7(2):136-41. PubMed ID: 16499283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice.
    El-Ghorr AA; Williams RM; Heap C; Norval M
    FEMS Immunol Med Microbiol; 2000 Dec; 29(4):255-61. PubMed ID: 11118905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.
    Ferenczy MW
    Curr Pharm Des; 2007; 13(19):1975-88. PubMed ID: 17627531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial.
    Gorfinkel IS; Aoki F; McNeil S; Dionne M; Shafran SD; Zickler P; Halperin S; Langley J; Bellamy A; Schulte J; Heineman T; Belshe R
    Int J STD AIDS; 2013 May; 24(5):345-9. PubMed ID: 23970700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inactivated herpes simplex virus types 1 and 2 divaccine as an agent for effective immunoprophylaxis of recurrent genital herpes].
    Barinskiĭ IF; Makhmudov FR
    Vopr Virusol; 2010; 55(1):35-40. PubMed ID: 20364670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vitaherpavac is the first Russian herpes simplex virus vaccine obtained on the Vero B continuous cell line].
    Barkhaleva OA; Ladyzhenskaia IP; Vorob'eva MS; Shalunova NV; Podcherniaeva RIa; Mikhaĭlova GR; Khorosheva TV; Barinskiĭ IF
    Vopr Virusol; 2009; 54(5):33-7. PubMed ID: 19882901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.